Abstract
So far, no combination of endocrine treatments has been routinely used in the therapy of breast Cancer. It was, therefore, our interest to determine whether the combination of the antiprogestin, onapristone (ON), and the pure antiestrogen, ICI 164384 (ICI), might provide a more effective therapy than either monotherapy in experimental mammary tumors containing both estrogen and progesterone receptors. In the MXT-mammary tumor of the mouse, ON (5 mg/kg) administered for 3 weeks exerted an ovariectomy-like antitumor effect (56% inhibition), whereas ICI (30 mg/kg) was weakly effective (28% inhibition). The combination of ON and ICI was, however, distinctly more effective than the monotherapies or ovariectomy, causing 78% inhibition. A similar potentation of antitumor effect by the combination was manifested in the dimethylbenzanthracene-induced mammary tumor of the rat when ON (5 mg/kg) and ICI (30 mg/kg) were administered once daily for 4 weeks (s.c.). The remission rates of tumors found after treatment with ICI, ON, the combination and ovariectomy (complete and partial remission) were 15%, 46%, 71% and 100% respectively. In the animals bearing DMBA-induced tumors, treatment with ON alone significantly increased the serum levels of luteinizing hormone and prolactin, but caused only a slight increase in the peripheral levels of estradiol and progesterone. ON had no appreciable effect on the uterine and ovarian weights. ICI reduced the uterine weight and the serum progesterone level. In the combination with ON, ICI reversed the effect of ON on the progesterone level without influencing the luteinizing harmone and prolactin levels. These findings suggest that the augmentation of antitumor effectiveness by the combination of two antihormones can be ascribed not only to their effects at estrogen- and progester-one-receptor-binding sites, but also to the decrease in the peripheral level of progesterone. Thus, an appropriate combination of antiprogestin and pure antiestrogen may be useful in the management of breast cancer.
Similar content being viewed by others
References
Angerer E von, Knebel N, Kager M, Ganß B (1990) 1-Aminoalkyl-2-phenylindoles as novel pure estrogen antagonists. J Med Chem 33:2635–2640
Bakker GH, Setyono-Han B, Jong FH de, Klijn JGM (1987) Mifepristone in treatment of experimental breast cancer in rats. In: Klijn JGM et al (eds) Hormonal manipulation of cancer: peptides, growth factors, and new (anti) steroidal agents. Raven Press, New York, pp 39–45
Bakker GH, Setyono-Han B, Portengen H, Jong FH de, Foekens JA, Klijn JGM (1989) Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors. Endocrinology 125:1593–1598
Furr BJA, Jordan VC (1984) Pharmacology and clinical use of tamoxifen. Pharmacol Ther 25:127–205
Gottardis MM, Ricchio ME, Satyaswaroop PG, Jordan VC (1990) Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (En Ca 101) in athymic mice. Cancer Res 50:3189–3192
Jordan VC, Koerner S (1976) Tamoxifen as an antitumour agent: role of oestradiol and prolactin. J Endocrinol 68:305–311
Klijn JGM, Jong FH de, Bakker GH, Lamberts SWJ, Rodenburg CJ, Alexieva-Figusch J (1989) Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res 49:2851–2856
McGuire WL (1980) An update on estrogen and progesterone receptors in prognosis for primary and advanced breast cancer. In: Iacobelli et al (eds) Hormones and cancer. Raven Press, New York, pp 337–343
Michna H, Gehring S, Kühnel W, Nishino Y, Schneider MR (1992a) The antitumor potency of progesterone antagonist is due to their differentiation potential. J Steroid Biochem Mol Biol 43:203–210
Michna H, Nishino Y, Neef G, McGuire WL, Schneider MR (1992b) Progesterone antagonists: tumor-inhibiting potential and mechanism of action. J Steroid Biochem Mol Biol 41:339–348
Nishino Y, Michna H, Schneider MR, Hasan SH, El Etreby MF (1989) Studies on the tumor-inhibiting effect of a new antiprogestin, ZK 98299 in female bearing DMBA-induced mammary tumors (abstract). Acta Endocrinol [Suppl 1] 120:236–237
Nishino Y, Schneider MR, Michna H, Angerer E von (1991) Pharmacological characterization of a novel oestrogen antagonist, ZK 119010, in rats and mice. J Endocrinol 130:409–414
Romieu G, Maudelonde T, Ulmann A, Pujol H, Grenier J, Cavalie G, Khalaf S, Rochefort H (1987) The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bull Cancer 74:455–461
Schneider MR, Michna H, Nishino Y, El Etreby MF (1989) Antitumor activity of the progesterone antagonists ZK 98299 and RU 38486 in the hormone-dependent MXT mammary tumor model of the mouse and the DMBA- and the NMU-induced mammary tumor models of the rat. Eur J Cancer Clin Oncol 25:691–701
Schneider MR, Horn D, Michna H, Nishino Y, Vollmer G, Angerer E von (1992 a) Endocrine activity and tumor-inhibiting properties of the nonsteroidal pure antiestrogen ZK 119010 (abstract). Acta Endocrinol [Suppl 4] 126:84
Schneider MR, Michna H, Habenicht UF, Nishino Y, Grill HJ, Pollow K (1992 b) The tumor-inhibiting potential of the progesterone antagonist onapristone in the human mammary carcinoma T61 in nude mice. J Cancer Clin Oncol 118:187–189
Thomas M, Monet JD (1992) Combined effects of RU486 and tamoxifen on the growth and cell cycle phases of the MCF-7 cell line. J Clin Endocrinol Metab 75:865–870
Wakeling AE, Bowler J (1987) Steroidal pure antioestrogen. J Endocrinol 112:R7-R10
Wakeling AE, Bowler J (1988) Biology and mode of action of pure antioestrogens. J steroid Biochem 30:141–147
Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867–3873
Welsh TH Jr, Zhuang LZ, Hsueh AJW (1983) Estrogen augmentation of gonadotropin-stimulated progestin biosynthesis in cultured rat granulosa cells. Endocrinology 112:1916–1924
Welsh TH Jr, Jia XC, Jones PBC, Zhuang LZ, Hsueh AJW (1984) Disparate effects of triphenylethylene antiestrogens on estrogen and progestin biosyntheses by cultured rat granulosa cells. Endocrinology 115:1275–1282
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nishino, Y., Schneider, M.R. & Michna, H. Enhancement of the antitumor efficacy of the antiprogestin, onapristone, by combination with the antiestrogen, ICI 164384. J Cancer Res Clin Oncol 120, 298–302 (1994). https://doi.org/10.1007/BF01236387
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01236387